Objectives Dyslipidemia represents a major health issue in psychiatry. We determined whether weighted polygenic risk scores (wPRSs) combining multiple single-nucleotide polymorphisms (SNPs) associated with lipid levels in the general population are associated with lipid levels [highdensity lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), and triglycerides] and/or dyslipidemia in patients receiving weight gain-inducing psychotropic drugs. We also determined whether genetics improve the predictive power of dyslipidemia.
Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs Objectives Dyslipidemia represents a major health issue in psychiatry. We determined whether weighted polygenic risk scores (wPRSs) combining multiple single-nucleotide polymorphisms (SNPs) associated with lipid levels in the general population are associated with lipid levels [highdensity lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), and triglycerides] and/or dyslipidemia in patients receiving weight gain-inducing psychotropic drugs. We also determined whether genetics improve the predictive power of dyslipidemia.
Patients and methods The influence of wPRS on lipid levels was firstly assessed in a discovery psychiatric sample (n = 332) and was then tested for replication in an independent psychiatric sample (n = 140). The contribution of genetic markers to predict dyslipidemia was evaluated in the combined psychiatric sample.
Results wPRSs were significantly associated with the four lipid traits in the discovery (P ≤ 0.02) and in the replication sample (P ≤ 0.03). Patients whose wPRS was higher than the median wPRS had significantly higher LDL, TC, and triglyceride levels (0.20, 0.32 and 0.26 mmol/l, respectively; P ≤ 0.004) and significantly lower HDL levels (0.13 mmol/l; P < 0.0001) compared with others. Adding wPRS to clinical data significantly improved dyslipidemia prediction of HDL (P = 0.03) and a trend for improvement was observed for the prediction of TC dyslipidemia (P = 0.08).
Conclusion Population-based wPRSs have thus significant effects on lipid levels in the psychiatric population. As genetics improved the predictive power of dyslipidemia development, only 24 patients need to be genotyped to prevent the development of one case of HDL hypocholesterolemia. If confirmed by further prospective investigations, the present results could be used for individualizing psychotropic treatment. Pharmacogenetics and Genomics 27:464-472 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
Cardiovascular diseases have become a major public health burden, with their prevalence increasing considerably over the past decades [1, 2] . Dyslipidemia, in particular abnormal plasma levels of circulating lipoproteins, is a clinical condition contributing to the development of atherosclerosis and cardiovascular diseases, for example, coronary artery diseases, strokes, and peripheral artery diseases [3] [4] [5] [6] [7] [8] . In addition to being influenced by environmental factors such as diet, lifestyle, and other environmental factors, plasma lipid levels are determined by the genetic background as well [9] . Although several forms of monogenic dyslipidemia associated with critical lipid level changes have been described, the most prevalent form of dyslipidemia has polygenic causes, resulting from the combination of many common, rare, and copy number genetic variants with a substantial contribution of environmental factors [9] .
In the psychiatric population, the use of psychotropic medications such as antipsychotics (most atypical but also some typical), mood stabilizers (e.g. lithium and valproate), and some antidepressants (e.g. mirtazapine) worsen patients' metabolic condition (e.g. weight gain and/or alteration of lipid and glucose metabolism) [10, 11] . Dyslipidemia, defined as high total cholesterol (TC), low-density lipoprotein (LDL)-cholesterol, triglyceride (TG), and/or low high-density lipoprotein (HDL)-cholesterol levels, constitutes a considerable risk factor for cardiovascular diseases in the psychiatric population as its prevalence was shown to increase as much as 60% [12] . Some factors were associated with psychotropic Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.pharmacogeneticsandgenomics.com.
drug-induced metabolic complications, including female sex, low baseline BMI, young age, or non-Caucasian ethnicities [13] . In addition, many genetic susceptibilities as variations in pharmacodynamic receptors or in energy homeostasis regulating genes were associated with metabolic adverse effects [14] [15] [16] [17] [18] . For instance, previous studies demonstrated the influence of 5HT 2C serotonin and H 1 histamine receptors on weight gain induced by psychotropic drugs [19, 20] . Although mechanisms underlying psychotropic-induced dyslipidemia are only partially understood, recent studies suggested a role of the sterol regulatory element-binding protein pathway [21] . Thus, olanzapine, clozapine, and risperidone were shown to promote the up-regulation of sterol regulatory element-binding protein, leading to enhanced lipid and cholesterol synthesis in mice [22, 23] .
With the rapid emergence of genome-wide association studies (GWAS), many genetic variants in association with metabolic phenotypes were discovered in the last decade [24] [25] [26] . Two recent GWAS meta-analyses from the Global Lipids Genetics Consortium and the Engage Consortium were conducted to reveal associations between abnormal lipid levels and single-nucleotide polymorphisms (SNPs) in the general population [27, 28] . When considered individually, these genetic variants have shown minor effects on lipid phenotypes. As an alternative method of testing individual SNP effect, integrating data from numerous SNPs in the construction of a polygenic risk score (PRS) allows to better integrate the global information of these numerous little effects [29] , with small effects increasing the consistency and power to determine genetic risk in polygenic diseases such as dyslipidemia [30] . Although several PRSs were determined as significant predictors of obesity, diabetes, and dyslipidemia [31] [32] [33] , associations between PRS and dyslipidemia among the psychiatric population have never been established.
The aim of the present study was to investigate whether PRSs combining multiple risk-associated SNPs from two lipid meta-analyses were associated with dyslipidemiarelated traits (HDL, LDL, TC, and TG) in patients from Lausanne University Hospital receiving psychotropic drugs known to induce worsening of metabolic parameters. Furthermore, the predictive power of models containing only clinical data was compared with models including both clinical and genetic data to examine whether models including genetics could be useful enough to be applied in clinical settings. A meta-analysis of 60 studies was performed by The Global Lipids Genetics Consortium with data from 188 577 individuals of European, East Asian, South Asian, and African ancestry using both GWAS and MetaboChip array genotyping data [28] . In addition, a second metaanalysis was conducted by the Engage Consortium with a set of 62 166 individuals of European ancestry from 22 GWAS [27] . Both population-based samples were used to select genetic variants associated with lipid levels. In the present study, β-coefficients (i.e. allele effects) were used to assign weights to each variant for the calculation of PRS in the psychiatric samples. 
Patients and methods

Statistical analyses
For the assessment of the influence of genetic parameters on dyslipidemia among psychiatric patients throughout the psychotropic treatment duration, generalized additive mixed models (GAMMs) were used, adjusting for covariates possibly associated with lipid parameters, that is, BMI, age, sex, smoking status, and psychotropic drug class. GAMMs were implemented using the mgcv and the nlme packages in R (settings were fixed at package defaults) [36] , in which parameter uncertainties (confidence intervals and P values) were computed using up to 100 000 bootstrap replicates with replacement, performed on patient level. The explained variance of weighted polygenic risk score (wPRS) on the four lipid variables was calculated by running GAMM with and without polygenic scores. All the statistical analyses were performed using Stata 14 (StataCorp., College Station Texas, USA) and R software (version 3.2.3; Teddington, Middlesex, UK). P values less than or equal to 0.05 of these two-sided models were considered as statistically significant.
Receiver operating characteristic (ROC) curves were used to compare the predictive power of models including only clinical data with models containing both clinical and genetic data using pROC and predictABEL R packages [37, 38] . More details about area under the curve (AUC) construction and interpretation are available in Supplementary Material (Supplemental digital content 1, http://links.lww.com/FPC/B279).
Evaluation of pharmacogenetic screening benefit
The clinical value of pharmacogenetic testing could be assessed by calculating the number needed to genotype (NNG). NNG defines the number of patients who would need to be genotyped to prevent dyslipidemia for one patient under psychotropic treatment [39] . Sensitivity for the calculation of the NNG was chosen according to best threshold coordinates for specificity and sensitivity of the ROC curve including genetics and clinical data.
Results
Characteristics of psychiatric samples
Demographic and clinical characteristics of the discovery (n = 332), replication (n = 140), and combined sample (n = 472) are presented in Supplementary Table S1 (Supplemental digital content 1, http://links.lww.com/FPC/B279). Table S14 , Supplemental digital content 1, http://links.lww.com/FPC/ B279). In the discovery sample, wPRS combined were also significantly associated with lipid levels (P ≤ 0.01) and replicated in the independent psychiatric replication sample (P ≤ 0.01) ( Table 1 ). In the combined psychiatric sample using wPRS combined , each additional risk allele significantly increased LDL, TC, and TG by 0.03, 0.04, and 0.04 mmol/l, respectively, and decreased HDL by 0.02 mmol/l (Table 1 ; P < 0.001, <0.00001, <0.0001 and <0.00001, respectively). As analyses on wPRS combined in the combined psychiatric sample showed significant associations and because estimates between the discovery and replication psychiatric samples were almost similar, further analyses were conducted using only wPRS combined in the combined psychiatric sample. In accordance with previous results, significant differences of the four lipid phenotype levels were observed between percentile groups (P ≤ 0.004) ( Table 2 and Fig. 1 ). Thus, patients whose wPRS was lower than the median value of all patients had significantly lower levels showing the importance to consider allele effects in a weighted approach. SNPs whose β values were higher than the percentile 95 of all β values are lying in well-known genes involved in the regulation of lipid homeostasis, as for instance in the lipoprotein lipase, in the LDL receptor, or in the apolipoprotein E (Supplementary Table S21 , Supplemental digital content 1, http://links.lww.com/FPC/B279).
Number needed to genotype
To detect whether genotyping would be useful as a routine test, the NNG for HDL was calculated (Table 3 ).
In the combined psychiatric sample, 24 patients would be needed to be genotyped to avoid HDL hypocholesterolemia for one patient.
Discussion
The present study shows that wPRS constructed with lipid-associated SNPs from population-based samples had a significant influence on HDL, LDL, TC, and TG levels in the psychiatric population receiving psychotropic treatment inducing metabolic disturbances. Moreover, adding genetics to clinical models significantly improved HDL hypocholesterolemia prediction and a trend for improvement was observed for the prediction of TC dyslipidemia.
In the present psychiatric sample, dyslipidemia prevalence for TC, LDL, HDL, and TG was higher than reported in the Recovery After an Initial Schizophrenia Episode study [12] , possibly because of the shorter lifetime exposure to psychotropic treatment in the latter (< 6 months) than in the present psychiatric sample (∼8 years). In contrast, in accordance with the latter study [12] , only a small proportion of patients (< 7%) received lipid-lowering agent(s), corresponding to 14% of patients with hypercholesterolemia. A significant increase in the incidence of dyslipidemia was observed over time despite the worrisome prevalence already observed at baseline. This emphasizes the importance to prospectively monitor metabolic (including lipid) parameters during psychotropic treatment in each patient starting psychotropic medication [40] . Although most patients were not drug naive before starting the current psychotropic treatment, our results within this observational psychiatric sample reflected real medical conditions in clinical practice. In addition, the present psychiatric sample was clinically heterogeneous in terms of drug classes (i.e. antipsychotics, mood stabilizers, and antidepressants) and of diagnoses (i.e. bipolar disorder, major depression, and schizophrenia). However, diagnosis was not identified as a moderator of psychotropic druginduced metabolic disturbances [41, 42] . Moreover, although antipsychotic drugs are known to be associated with different degrees of weight gain, larger studies and meta-analyses are needed to determine how these drugs alter the lipid profile and whether their rank of risks is similar to weight gain. Thus, further studies are warranted to determine whether the alteration of the lipid profile depends on the drug class. In contrast, the clinical heterogeneity of the present sample also constitutes strength, reflecting real clinical conditions.
To date, a large number of lipid-associated SNPs discovered among general population accounted for 6.6, 5.7, 8.2, and 5.0% for HDL, LDL, TC, and TG, respectively, of the variance explained by wPRS [43] . Results obtained from our psychiatric samples showed a slightly smaller explained variability for lipid phenotypes (4.3, 3.4, 3.3, and 4.8%, respectively). As the explained variability by genetics was strongly decreased in unweighted PRS, our results are in accordance with the importance of weighted approaches in PRS analyses. The difference between our results compared with population-based wPRS on lipids may be not only because of a lower number of patients in our psychiatric sample but also to the use of nonappropriate allele estimates. Thus, population-based estimates could Generalized additive mixed models were performed with polygenic risk score as a categorical variable with two groups. CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SNP, single-nucleotide polymorphism; TC, total cholesterol; TG, triglyceride; wPRS, weighted polygenic risk score; wPRS < p50, group of patients whose wPRS was lower than the median of all patients wPRS; wPRS ≥ p50, group of patients whose wPRS was higher or equal to the median of all patients wPRS; wPRS < p25, group of patients whose wPRS was lower than the percentile 25 of all patients wPRS; wPRS > p75, group of patients whose wPRS was higher than the percentile 75 of all patients wPRS; wPRS < p10, group of patients whose wPRS was lower than the percentile 10 of all patients wPRS; wPRS > p90, group of patients whose wPRS was higher than the percentile 90 of all patients wPRS.
either under-represent or over-represent the influence of some SNPs in the psychiatric population, which may flatten the explained variability. As a matter of fact, the psychiatric population displays a greater influence of some genetic variants on metabolic features than does the general population, possibly because of an intricate interaction between the psychiatric illness and metabolic regulation [16, 44] as well as a higher prevalence of metabolic abnormalities in this specific population [45] . As a consequence, a wPRS constructed with estimates from psychiatric samples would be more pertinent and would certainly enhance the explained variability of genetics in this high-risk population. Of note, it is very likely that the consideration of additional genetic variants (e.g. SNPs associated with psychotropic drug-induced weight gain and metabolic abnormalities in genes such as FTO, LEP, LEPR, or HTR2C [46, 47] ) in the weighted polygenic risk score may help to improve the predictive power of weighted polygenic risk score on dyslipidemia. Unfortunately, such promising variants could not be included in PRSs because no allele effect (β-coefficient from GWAS) for these SNPs was available in the literature. In addition, SNPs from candidate gene studies arose from heterogeneous studies in terms of drugs and of treatment durations, and these studies were limited by a lack of replication and a poor sample size. Unfortunately, no GWAS on lipid traits has been yet performed in either drug-free psychiatric population or patients receiving psychotropic drugs inducing metabolic disturbances. Such studies and meta-analyses conducted on lipid levels would help to provide more accurate allelic estimates. In the present study, most of the lipid variance explained by genetics was driven by a very low number of SNPs with large effects, localized in well-known genes involved in lipid homeostasis and/or associated with cardiovascular risk [48] . Copy number variants, insertions or deletions, not taken into account in this study, might further increase explained variability. Moreover, whether selecting more than one single SNP per gene would increase the explained variability remains unknown. Finally, the Evolution of lipid variables during psychotropic treatment, according to extreme groups of PRS. Median, interquartile, and number of observations are indicated for each box. Months were defined as follows: month [0]: day 0, month [1] : ≥ 10 and <45 days, month [2] [3] : ≥ 45 and <135 days, and month [6] [7] [8] [9] [10] [11] [12] : ≥ 135 and <535 days. Patients taking lipid-lowering medication were excluded. Only fasting patients were included for TG analyses. HDL, high-density lipoprotein; LDL, low-density lipoprotein; PRS, polygenic risk score; 10% PRS, PRS lower than the 10th percentile; 90% PRS, PRS higher than the 90th percentile; TC, total cholesterol; TG, triglyceride.
explained variability could be increased by adding new additional common variants (probably with modest effects), rare variants (probably with large effects), methylation profile as well as more clinical lipid-related characteristics.
Several reports recently described the use of predictive models containing genetics in cardiovascular disease to prevent long-term health consequences [49] [50] [51] . Although wPRSs were highly associated with lipid levels in the present Receiver operating characteristic curves for abnormal lipid levels in the combined sample, defined by abnormal levels and/or by the prescription of a lipid-lowering comedication. Solid curves correspond to the model including clinical and genetics components, whereas the dashed curves include only clinical values. Only fasting patients were included for TG analyses. Low HDL-cholesterol level, that is, HDL hypocholesterolemia was defined as less than 1 mmol/l and/or prescription of a lipid-lowering agent; high LDL-cholesterol level, that is, LDL hypercholesterolemia was defined as at least 3 mmol/l and/or prescription of a lipid-lowering agent; high TG level, that is, hypertriglyceridemia was defined as at least 2 mmol/l and/or prescription of a lipid-lowering agent; and high TC level, that is, hypercholesterolemia was defined as at least 5 mmol/l and/or prescription of a lipid-lowering agent [34] , according to European Society of Hypertension/European Society of Cardiology guidelines [35] . AUC, area under the curve; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TC, total cholesterol; TG, triglyceride.
study, models containing both clinical and genetic components in the discovery and replication samples did not show a significant increase in the power to predict lipid phenotypes compared with models containing clinical variables only. However, in the combined sample, AUCs were significantly increased for HDL and a trend of increase was observed for TC, suggesting that statistical power could be improved by increasing population samples. In addition, adding more dyslipidemia-associated genetic markers as well as covariate risk factors for dyslipidemia development could also improve the prediction. Of note, AUC for HDL model including both genetics and clinical variables in the combined sample was higher than 0.75 and sensitivity, specificity, and accuracy were higher than 70%, indicating that the prediction was informative and useful enough [52] . On the basis of the present results, 24 patients would be needed to be genotyped to avoid HDL hypocholesterolemia for one patient [53] . Thus, additional studies with larger sample sizes are needed to replicate the present findings and to identify new lipid-associated variants before the additive value of including genetic information in predictive models is transposable to routine clinical practice. In addition, larger studies are warranted to investigate the influence of wPRS on lipid levels in specific subgroups of patients (e.g. drug-stratified and/or diagnosis-stratified samples).
Results of the present study should be considered with the following limitations. First, the study was restricted to European patients, which impedes extrapolation to other ethnicities. Second, effects of environmental changes such as physical exercise or diet habits throughout the treatment, which could have influenced the evolution of lipid levels, were not taken into account. The strength of our study is the use of a weighted approach for the PRS. In addition, therapeutic drug monitoring was performed to ascertain compliance to exclude false negative, that is, patients who did not develop dylipidemia because they did not take the drug, an important factor to consider in the psychiatric population.
Conclusion
We showed an influence of PRS built from variants related to lipid traits in population-based samples on lipid levels in the psychiatric population. Moreover, adding genetic information to clinical variables may improve the prediction of HDL hypocholesterolemia in psychiatric patients treated with weight gain-inducing psychotropic drugs. Forthcoming work is needed to examine whether predictive models are accurate and useful enough for the clinical purpose of individualizing psychiatric treatment. Number needed to genotype calculations were done using sensitivity of the best threshold coordinates in each sample for high-density lipoprotein dyslipidemia development.
